Kwality Pharmaceuticals' Credit Rating Upgraded to [ICRA]BBB+ (Stable) Following Strong Growth and Financial Metrics

Kwality Pharmaceuticals' Credit Rating Upgraded to [ICRA]BBB+ (Stable) Following Strong Growth and Financial Metrics​

Kwality Pharmaceuticals Ltd. (KPL) has received a credit rating upgrade on its bank loan facilities from ICRA Limited. The rating action, effective May 7, 2026, upgraded the ratings and removed the company from the 'Issuer Not Cooperating' category.

The revised ratings confirm the company's operational standing and financial health, reflecting its performance and future growth trajectory in the pharmaceutical sector.

Rating Summary and Financial Enhancement​

ICRA Limited revised the ratings across two major instruments, significantly enhancing the total rated amount.


The ratings for the Long-term - Fund-based Term Loans were upgraded to [ICRA]BBB+ (Stable), while the Long-term/Short-term - Fund-based/Non-fund based limits were upgraded to [ICRA]BBB+ (Stable)/[ICRA]A2.

Factors Driving the Upgrade​

ICRA cited KPL's extensive industry experience, diversified geographical reach, and strong financial fundamentals as key contributors to the upgraded rating.

KPL’s operational strength is supported by a track record spanning more than four decades. The company maintains a well-diversified geographical presence across semi-regulated markets, including Asia, Africa, and Latin America. Exports, which account for approximately 50% of annual revenues, underscore the company's robust international market linkages.

The company’s product portfolio is noted for its complexity, with injectables generating over 50% of revenues in 9M FY2026. KPL has developed over 1,000 formulations across more than 25 therapeutic areas.

Financially, KPL demonstrated significant growth. The company achieved a compounded annual growth rate (CAGR) of 21% between FY2023 and FY2025, reporting a 36% revenue growth to Rs. 346.0 crore in 9M FY2026. The financial profile remains healthy, citing a total debt/OPBDITA of 1.1 times and an interest cover of 8.8 times in H1 FY2026. Furthermore, the liquidity position was assessed as adequate, supported by cash, cash equivalents, and liquid investments totaling Rs. 34.1 crore as of September 30, 2025.

Challenges and Outlook​

While the rating upgrade was positive, ICRA also highlighted specific challenges. KPL’s operations remain exposed to the high competitive intensity and regulatory changes in the pharmaceutical industry, including pricing caps.

A notable constraint cited is the high working capital intensity, with an NWC/OI of 50.2% in FY2025. This elevated intensity is partly attributed to the company's growth phase in semi-regulated markets and an increased number of Stock-Keeping Units (SKUs). Additionally, the company's profitability remains susceptible to fluctuations in raw material prices and foreign exchange due to its reliance on imports.

The Stable outlook reflects the belief that KPL will benefit from its complex product portfolio and expanding presence across emerging markets, which is expected to continue supporting growth in revenues and profitability over the near to medium term.

KPL Stock Price Movement​

As of 11:01 AM, shares of Kwality Pharmaceuticals Limited are slipping by 0.68% in live trading, currently at ₹1715.3. The equity trades on a volume of 2,831 shares, shedding value during the ongoing morning session.